Soft and absorbent tissue products

Abstract

Softening compositions for tissues, particularly facial tissues, include a combination of polysiloxanes and one or both of a polyalkylene oxide and a fatty alkyl derivative. The softening compositions can contain from about 30 to about 75 weight percent polysiloxane, from about 0 to about 60 weight percent polyalkylene oxide and from about 0 to about 60 weight percent fatty alkyl derivative, wherein the combined amount of the polyalkylene oxide and the fatty alkyl derivative is about 25 weight percent or greater. The resulting tissues have good softness and wettability.

1 . A tissue sheet having from about 0.5 to about 10 dry weight percent of a topically-applied softening composition which comprises, on a solids basis, from about 30 to about 75 weight percent of one or more polysiloxanes, from about 0 to about 60 weight percent of one or more polyalkylene oxides and from about 0 to about 60 weight percent of one or more fatty alkyl derivatives, wherein the combined amount of the polyalkylene oxide(s) and the fatty alkyl derivative(s) is about 25 weight percent or greater. 
     
     
         2 . The tissue sheet of  claim 1  wherein one or more of the polysiloxanes has the following general structure: 
       
         
           
           
               
               
           
         
       
       wherein:
 “m” is from 10 to 100,000; 
 “n” is from 1 to 10,000; 
 “p” is from 0 to 1,000; 
 “A” and “B” are independently a hydroxyl, C 1  to C 20  or R 2 ; 
 R 1 , R 2  and R 3  are distributed in random or block fashion; 
 R 1  is a C 1  to C 8  radical, which can be straight chain, branched or cyclic; 
 R 2  is a C 1  to C 8  radical, which can be straight chain, branched or cyclic, or of the structure: 
 
       
         
           
           
               
               
           
         
         
           wherein 
           R 4  and R 5  are independently a C 2  to C 8  alkylene diradical, which can be straight chain or branched, substituted, or unsubstituted; 
           X is an oxygen or N—R 8 ; 
           R 6 , R 7  and R 8  are independently hydrogen, a substituted or unsubstituted C 1  or C 2 , a substituted or unsubstituted straight chain or branched or cyclic C 3  to C 20  alkyl radical, or an acyl radical, such as an acetyl radical; and 
           “s” is 0 or 1; 
         
         R 3  is of the structure: R 9 —Y—[C 2 H 4 O] r —C 3 H 6 O] q —R 10  
 wherein 
 Y is an oxygen or N—R 11 ; 
 R 9  is a C 2  to C 8  alkylene diradical, which can be straight chain or branched, substituted or unsubstituted; 
 R 10  and R 11 , are independently hydrogen, a substituted or unsubstituted C 1  or C 2 , a substituted or unsubstituted, straight chain or branched or cyclic C 3  to C 20  alkyl radical; 
 “r” is from 1 to 100,000; and 
 “q” is from 0 to 100,000. 
 
       
     
     
         3 . The tissue of  claim 2  wherein R 2  is an alkylene substituted with a di-amine or a mono-amine. 
     
     
         4 . The tissue of  claim 2  wherein R 2 =R 1  and “A” and “B” are a nitrogen quaternium. 
     
     
         5 . The tissue of  claim 1  wherein the polyalkylene oxide has the following general structure:
   R 12 —[C 2 H 4 O] i —[C 3 H 6 O] j —[C t H 2t O] v —R 13      
       wherein:
 R 12  and R 13  are independently a hydrogen, a substituted or unsubstituted C 1  to C 6  alkyl radical, a straight chain or branched C 1  to C 6  alkyl radical, or a cyclic C 1  to C 6  alkyl radical; 
 “i”, “j” and “v” are independently from 0 to 100,000, with the oxide moieties are distributed along the polymer backbone randomly or as blocks; 
 “i+j+v” is equal to or greater than 10; and 
 “t” is from 4 to 10. 
 
     
     
         6 . The tissue of  claim 4  wherein the polyalkylene oxide is a polyethylene oxide or a polyethylene glycol. 
     
     
         7 . The tissue of  claim 6  wherein the polyethylene oxide or polyethylene glycol has a molecular weight greater than 600. 
     
     
         8 . The tissue of  claim 4  wherein the polyalkylene oxide is polyethylene glycol. 
     
     
         9 . The tissue of  claim 1  wherein the polyalkylene oxide is a solid at room temperature. 
     
     
         10 . The tissue of  claim 1  wherein the fatty alkyl derivative has the following general structure:
   R 14 -G   
       wherein:
 R 14  is a C 8  to C 40  alkyl radical, which can be substituted or unsubstituted, primary, secondary or tertiary; straight chain, branched or cyclic; and 
 “G” is hydroxy, amine, sulfonate, sulfate, phosphate, acid or acid derivative, or -Q-[C 2 H 4 O] i —[C 3 H 6 O] j —[C t H 2t O] v —R 13  radical;
 wherein 
 “Q” is an oxygen radical, an NH radical or N—[C 2 H 4 O} i —[C 3 H 6 O] j —[C t H 2t O] v —R 13  radical; 
 R 13  is a hydrogen, a substituted or unsubstituted C 1  to C 6  alkyl radical, a straight chain or branched C 1  to C 6  alkyl radical, or a cyclic C 1  to C 6  alkyl radical; 
 “i”, “j” and “v” are independently from 0 to 100,000, where the oxide moieties are distributed along the polymer backbone randomly or as blocks; 
 “i+j+v” is equal to or greater than 10; and 
 “t” is from 4 to 10. 
 
 
     
     
         11 . The tissue of  claim 1  wherein the fatty alkyl derivative is an ethoxylated alcohol or a mixtures of ethoxylated alcohols. 
     
     
         12 . The tissue of  claim 11  wherein an ethoxylated alcohol has a carbon chain length of 12 or greater. 
     
     
         13 . The tissue of  claim 11  wherein the fatty alkyl derivative is an ethoxylated tridecyl alcohol. 
     
     
         14 . The tissue of  claim 11  wherein the fatty alkyl derivative is an ethoxylated cetyl alcohol. 
     
     
         15 . The tissue of  claim 10  wherein the fatty alkyl derivative is a solid at room temperature. 
     
     
         16 . The tissue of  claim 1  wherein the polysiloxane is an amino-derivatized polysiloxane and the fatty alkyl derivative is an alkylenoxylated alcohol. 
     
     
         17 . The tissue of  claim 1  wherein the polysiloxane is an amino-derivatized polysiloxane and the fatty alkyl derivative is an alkylenoxylated amine. 
     
     
         18 . The tissue of  claim 1  wherein the tissue softening composition comprises about 70 weight of an amino-polysiloxane and about 30 weight percent of an ethoxylated alcohol or a mixture of ethoxylated alcohols. 
     
     
         19 . The tissue of  claim 18  wherein the ethoxylated alcohols are in solid form at room temperature. 
     
     
         20 . The tissue of  claim 1  wherein the tissue softening composition comprises from about 50 to about 70 weight percent of an amino-polysiloxane and from about 30 to about 50 weight percent polyethylene glycol. 
     
     
         21 . The tissue of  claim 20  wherein the polyethylene glycol is a solid at room temperature. 
     
     
         22 . The tissue of  claim 1  wherein the tissue softening composition comprise from about 50 to about 70 weight percent of an amino-polysiloxane and from about 30 to about 50 weight percent of a mixture of at least one polyethylene glycol and at least one fatty alkyl derivative 
     
     
         23 . The tissue of  claim 22  wherein the polyethylene glycol and fatty alkyl derivative are in solid form at room temperature. 
     
     
         24 . A softening composition which comprises, on a solids basis, from about 30 to about 75 weight percent of one or more polysiloxanes, from about 0 to about 60 weight percent of one or more polyalkylene oxides and from about 0 to about 60 weight percent of one or more fatty alkyl derivatives, wherein the combined amount of the polyalkylene oxide(s) and the fatty alkyl derivative(s) is about 25 weight percent or greater. 
     
     
         25 . The composition of  claim 24  wherein one or more of the polysiloxanes has the following general structure: 
       
         
           
           
               
               
           
         
       
       wherein:
 “m” is from 10 to 100,000; 
 “n” is from 1 to 10,000; 
 “p” is from 0 to 1,000; 
 “A” and “B” are independently a hydroxyl, C 1  to C 20  or R 2 ; 
 R 1 , R 2  and R 3  are distributed in random or block fashion; 
 R 1  is a C 1  to C 8  radical, which can be straight chain, branched or cyclic; 
 R 2  is a C 1  to C 8  radical, which can be straight chain, branched or cyclic, or of the structure: 
 
       
         
           
           
               
               
           
         
         
           wherein 
           R 4  and R 5  are independently a C 2  to C 8  alkylene diradical, which can be straight chain or branched, substituted, or unsubstituted; 
           X is an oxygen or N—R 8 ; 
           R 6 , R 7  and R 8  are independently hydrogen, a substituted or unsubstituted C 1  or C 2 , a substituted or unsubstituted straight chain or branched or cyclic C 3  to C 20  alkyl radical, or an acyl radical, such as an acetyl radical; and 
           “s” is 0 or 1; 
         
         R 3  is of the structure: R 9 —Y—[C 2 H 4 O] r —[C 3 H 6 O] q —R 10  
 wherein 
 Y is an oxygen or N—R 1 ; 
 R 9  is a C 2  to C 8  alkylene diradical, which can be straight chain or branched, substituted or unsubstituted; 
 R 10  and R 11 , are independently hydrogen, a substituted or unsubstituted C 1  or C 2 , a substituted or unsubstituted, straight chain or branched or cyclic C 3  to C 20  alkyl radical; 
 “r” is from 1 to 100,000; and 
 “q” is from 0 to 100,000. 
 
       
     
     
         26 . The composition of  claim 25  wherein R 2 =R 1  and “A” and “B” are a nitrogen quaternium. 
     
     
         27 . The composition of  claim 24  wherein the polyalkylene oxide has the following general structure:
   R 12 —[C 2 H 4 O} i —[C 3 H 6 O] j —[C t H 2t O] v —R 13      
       wherein:
 R 12  and R 13  are independently a hydrogen, a substituted or unsubstituted C 1  to C 6  alkyl radical, a straight chain or branched C 1  to C 6  alkyl radical, or a cyclic C 1  to C 6  alkyl radical; 
 “i”, “j” and “v” are independently from 0 to 100,000, with the oxide moieties are distributed along the polymer backbone randomly or as blocks; 
 “i+j+v” is equal to or greater than 10; and 
 “t” is from 4 to 10. 
 
     
     
         28 . The composition of  claim 24  wherein the fatty alkyl derivative has the following general structure:
   R 14 -G   
       wherein:
 R 14  is a C 8  to C 40  alkyl radical, which can be substituted or unsubstituted, primary, secondary or tertiary; straight chain, branched or cyclic; and 
 “G” is hydroxy, amine, sulfonate, sulfate, phosphate, acid or acid derivative, or -Q-[C 2 H 4 O] i —[C 3 H 6 O] j —[C t H 2t O] v —R 13  radical;
 wherein 
 “Q” is an oxygen radical, an NH radical or N—[C 2 H 4 O} i —[C 3 H 6 O] j —[C t H 2t O] v —R 13  radical; 
 R 13  is a hydrogen, a substituted or unsubstituted C 1  to C 6  alkyl radical, a straight chain or branched C 1  to C 6  alkyl radical, or a cyclic C 1  to C 6  alkyl radical; 
 “i”, “j” and “v” are independently from 0 to 100,000, where the oxide moieties are distributed along the polymer backbone randomly or as blocks; 
 “i+j+v” is equal to or greater than 10; and 
 “t” is from 4 to 10.